Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Vet Res. 2008 Mar;69(3):396-402. doi: 10.2460/ajvr.69.3.396.

Effect of intermittent oral administration of ponazuril on experimental Sarcocystis neurona infection of horses.

Author information

1
Department of Large Animal Clinical Sciences, University of Florida, Gainesville, FL 32610, USA.

Abstract

OBJECTIVE:

To evaluate the effect of intermittent oral administration of ponazuril on immunoconversion against Sarcocystis neurona in horses inoculated intragastrically with S neurona sporocysts.

ANIMALS:

20 healthy horses that were seronegative for S neurona-specific IgG.

PROCEDURES:

5 control horses were neither inoculated with sporocysts nor treated. Other horses (5 horses/group) each received 612,500 S neurona sporocysts via nasogastric tube (day 0) and were not treated or were administered ponazuril (20 mg/kg, PO) every 7 days (beginning on day 5) or every 14 days (beginning on day 12) for 12 weeks. Blood and CSF samples were collected on day - 1 and then every 14 days after challenge for western blot assessment of immunoconversion. Clinical signs of equine protozoal myeloencephalitis (EPM) were monitored, and tissues were examined histologically after euthanasia.

RESULTS:

Sera from all challenged horses yielded positive western blot results within 56 days. Immunoconversion in CSF was detected in only 2 of 5 horses that were treated weekly; all other challenged horses immunoconverted within 84 days. Weekly administration of ponazuril significantly reduced the antibody response against the S neurona 17-kd antigen in CSF. Neurologic signs consistent with EPM did not develop in any group; likewise, histologic examination of CNS tissue did not reveal protozoa or consistent degenerative or inflammatory changes.

CONCLUSIONS AND CLINICAL RELEVANCE:

Administration of ponazuril every 7 days, but not every 14 days, significantly decreased intrathecal anti-S neurona antibody responses in horses inoculated with S neurona sporocysts. Protocols involving intermittent administration of ponazuril may have application in prevention of EPM.

PMID:
18312139
DOI:
10.2460/ajvr.69.3.396
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center